Neurogene Inc. (NGNE)

Neurogene Inc. (NGNE) is a healthcare company (biotechnology) based in the United States. The share price is $22.85, down 1.95% on the day, which values the company at $472.91M. Price as of 17 Nov 2026, 17:28 UTC, from Yahoo Finance.

Key facts

Share price
$22.85−1.95% today
Market value
$472.91M
200-week average
$24.487% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Neurogene Inc. in more detail

NGNE trades at -4.6× next year's expected earnings. It sits 7% below its 200-week average of $24.48.

In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

1 of the superinvestors tracked here hold NGNE, including Julian and Felix Baker (0.2% of the portfolio).

Superinvestors holding NGNE

1 of the investors tracked here report a position in their latest 13F filing.

Neurogene Inc. (NGNE): questions and answers

What is Neurogene Inc.'s market cap?

Neurogene Inc. is valued at $472.91M at a share price of $22.85.

Is NGNE above its 200-week moving average?

No. NGNE is 6.7% below its 200-week average of $24.48. Long-term investors watch that line because strong companies rarely trade below it for long.

Does NGNE pay a dividend?

Neurogene Inc. does not currently pay a regular dividend.

Which famous investors own NGNE?

In their latest quarterly filings, Julian and Felix Baker (0.2% of the portfolio) hold NGNE. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Neurogene Inc. (NGNE) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/NGNE

Underlying data: Yahoo Finance; company filings with the SEC.